Conference Coverage

Study highlights need to investigate psoriasis treatment outcomes in skin of color patients

Publish date: March 9, 2018

 

REPORTING FROM ODAC 2018

dermnews@frontlinemedcom.com

SOURCE: Kaufman B et al. ODAC 2018

Pages

Recommended Reading

Make a PEST of your psoriasis patients
MDedge Rheumatology
CV risk factors go undiagnosed, untreated in many psoriatic patients
MDedge Rheumatology
Get ready for certolizumab for psoriasis
MDedge Rheumatology
Here comes bimekizumab, the newest IL-17 inhibitor
MDedge Rheumatology
Risankizumab outpaced ustekinumab for complete clearance of plaque psoriasis
MDedge Rheumatology
Biologics have best chance of achieving PASI 90 in psoriasis
MDedge Rheumatology
Ustekinumab quells aortic inflammation in patients with severe psoriasis
MDedge Rheumatology
Could guselkumab be a disease-modifying agent in plaque psoriasis?
MDedge Rheumatology
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
MDedge Rheumatology
Xeljanz: FDA panel recommends ulcerative colitis indication
MDedge Rheumatology